PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc., leading the transformation of clinical trials with a digital trials platform connecting patients, sites, and clinical trial teams, will demonstrate a number of integrated eClinical, telemedicine, and data...
AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms AVID200 demonstrated peripheral target engagement in a Phase 1 clinical trial in solid tumors AVID200 is undergoing additional Phase 1 testing in...
Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initial data from its ongoing Phase 2, placebo-controlled, clinical trial of...
Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy Patients demonstrated rapid and...
The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and...
Analyses of two international clinical trials predict response to asthma drug benralizumab by subpopulation of patients with COPD Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the U.S., according to the American Lung...
Email
Text